Loading...
Docoh

Yumanity Therapeutics (YMTX)

526 filings

Newest first
Filter options loading...
Top filers
Top filing types
Recent filing years
425
YMTX Yumanity Therapeutics Inc
23 Sep 22
Business combination disclosure
8:01am
8-K
YMTX Yumanity Therapeutics Inc
23 Sep 22
Regulation FD Disclosure
8:00am
425
YMTX Yumanity Therapeutics Inc
14 Sep 22
Business combination disclosure
4:04pm
8-K
YMTX Yumanity Therapeutics Inc
14 Sep 22
Kineta CSO Thierry Guillaudeux Invited to Participate at the 2nd Annual VISTA Virtual Symposium
4:01pm
425
YMTX Yumanity Therapeutics Inc
12 Sep 22
Business combination disclosure
4:01pm
8-K
YMTX Yumanity Therapeutics Inc
12 Sep 22
Kineta Announces Participation in the H.C. Wainwright 24th Annual Global Healthcare Conference
4:00pm
425
YMTX Yumanity Therapeutics Inc
29 Aug 22
Business combination disclosure
4:03pm
8-K
YMTX Yumanity Therapeutics Inc
29 Aug 22
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta
4:01pm
S-4
YMTX Yumanity Therapeutics Inc
28 Aug 22
Registration of securities issued in business combination transactions
8:00pm
10-Q
2022 Q2
YMTX Yumanity Therapeutics Inc
4 Aug 22
Quarterly report
5:12pm
8-K
YMTX Yumanity Therapeutics Inc
4 Aug 22
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
4:51pm
425
YMTX Yumanity Therapeutics Inc
20 Jul 22
Business combination disclosure
6:09am
8-K
YMTX Yumanity Therapeutics Inc
20 Jul 22
Regulation FD Disclosure
6:07am
4
Peters Richard
6 Jul 22
YUMANITY THERAPEUTICS / Richard Peters ownership change
4:54pm
425
YMTX Yumanity Therapeutics Inc
28 Jun 22
Business combination disclosure
4:03pm
8-K
YMTX Yumanity Therapeutics Inc
28 Jun 22
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
4:02pm
425
YMTX Yumanity Therapeutics Inc
17 Jun 22
Business combination disclosure
4:03pm
8-K
YMTX Yumanity Therapeutics Inc
17 Jun 22
Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit
4:02pm
8-K
YMTX Yumanity Therapeutics Inc
9 Jun 22
Submission of Matters to a Vote of Security Holders
4:06pm
4
Marie Epstein
6 Jun 22
YUMANITY THERAPEUTICS / Marie Epstein ownership change
9:49pm